Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
95,714,968
-
Total 13F shares
-
76,437,789
-
Share change
-
+850,032
-
Total reported value
-
$4,009,631,400
-
Put/Call ratio
-
77%
-
Price per share
-
$52.44
-
Number of holders
-
463
-
Value change
-
+$34,329,052
-
Number of buys
-
220
-
Number of sells
-
176
Institutional Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2025
As of 31 Dec 2025,
CRISPR Therapeutics AG - Common Stock (CRSP) was held by
463 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
76,437,789 shares.
The largest 10 holders included
ARK Investment Management LLC, BlackRock, Inc., Orbis Allan Gray Ltd, Capital International Investors, STATE STREET CORP, T. Rowe Price Investment Management, Inc., GSK plc, UBS Group AG, VANGUARD GROUP INC, and GEODE CAPITAL MANAGEMENT, LLC.
This page lists
467
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.